Compare Orchid Chemicals with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs NATCO PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD NATCO PHARMA ORCHID PHARMA LTD/
NATCO PHARMA
 
P/E (TTM) x -0.5 15.6 - View Chart
P/BV x 0.1 3.1 3.8% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ORCHID PHARMA LTD   NATCO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
NATCO PHARMA
Mar-18
ORCHID PHARMA LTD/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,080 18.0%   
Low Rs35671 5.2%   
Sales per share (Unadj.) Rs276.5592.1 46.7%  
Earnings per share (Unadj.) Rs-79.2188.4 -42.0%  
Cash flow per share (Unadj.) Rs-43.5206.3 -21.1%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9833.6 6.5%  
Shares outstanding (eoy) m70.4536.90 190.9%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x0.41.5 28.0%   
Avg P/E ratio x-1.44.6 -31.1%  
P/CF ratio (eoy) x-2.64.2 -62.1%  
Price / Book Value ratio x2.11.1 202.1%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m8,06732,311 25.0%   
No. of employees `0002.84.8 58.0%   
Total wages/salary Rs m2,5273,256 77.6%   
Avg. sales/employee Rs Th6,956.14,522.5 153.8%   
Avg. wages/employee Rs Th902.5674.0 133.9%   
Avg. net profit/employee Rs Th-1,993.01,439.0 -138.5%   
INCOME DATA
Net Sales Rs m19,47721,848 89.1%  
Other income Rs m407404 100.8%   
Total revenues Rs m19,88422,252 89.4%   
Gross profit Rs m1,1039,284 11.9%  
Depreciation Rs m2,519662 380.5%   
Interest Rs m5,227154 3,394.0%   
Profit before tax Rs m-6,2368,872 -70.3%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,920 -6.5%   
Profit after tax Rs m-5,5806,952 -80.3%  
Gross profit margin %5.742.5 13.3%  
Effective tax rate %2.021.6 9.3%   
Net profit margin %-28.731.8 -90.0%  
BALANCE SHEET DATA
Current assets Rs m11,01421,307 51.7%   
Current liabilities Rs m32,0605,920 541.6%   
Net working cap to sales %-108.170.4 -153.4%  
Current ratio x0.33.6 9.5%  
Inventory Days Days9573 129.5%  
Debtors Days Days34107 31.5%  
Net fixed assets Rs m29,44014,986 196.4%   
Share capital Rs m705369 190.9%   
"Free" reserves Rs m2,04330,353 6.7%   
Net worth Rs m3,80030,760 12.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51037,151 125.2%  
Interest coverage x-0.258.6 -0.3%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.6 71.2%   
Return on assets %-0.819.1 -4.0%  
Return on equity %-146.922.6 -649.8%  
Return on capital %-3.729.3 -12.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51310,322 72.8%   
Fx outflow Rs m5,6492,978 189.7%   
Net fx Rs m1,8657,343 25.4%   
CASH FLOW
From Operations Rs m1,6824,636 36.3%  
From Investments Rs m-9,860-11,155 88.4%  
From Financial Activity Rs m6,6446,509 102.1%  
Net Cashflow Rs m-1,535-18 8,527.8%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 4.6 7.8 58.7%  
FIIs % 3.3 16.6 19.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 26.0 212.7%  
Shareholders   84,811 25,395 334.0%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - TORRENT PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS